These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

490 related items for PubMed ID: 16176858

  • 1. [Type 2B and pseudo type 2B Von Willebrand disease; a report of three cases].
    Guermazi S, Conard J, Samama MM, Dellagi K.
    Pathol Biol (Paris); 2006 Apr; 54(3):159-65. PubMed ID: 16176858
    [Abstract] [Full Text] [Related]

  • 2. Measurement of von Willebrand factor binding to a recombinant fragment of glycoprotein Ibalpha in an enzyme-linked immunosorbent assay-based method: performances in patients with type 2B von Willebrand disease.
    Caron C, Hilbert L, Vanhoorelbeke K, Deckmyn H, Goudemand J, Mazurier C.
    Br J Haematol; 2006 Jun; 133(6):655-63. PubMed ID: 16704443
    [Abstract] [Full Text] [Related]

  • 3. Platelet activation and aggregation induced by recombinant von Willebrand factors reproducing four type 2B von Willebrand disease missense mutations.
    de Romeuf C, Hilbert L, Mazurier C.
    Thromb Haemost; 1998 Jan; 79(1):211-6. PubMed ID: 9459349
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Type 2B Hiroshima: a variant of von Willebrand disease characterized by chronic thrombocytopenia and the presence of all von Willebrand factor multimers in plasma.
    Takimoto Y, Imanaka F.
    Int J Hematol; 1999 Aug; 70(2):127-31. PubMed ID: 10497852
    [Abstract] [Full Text] [Related]

  • 8. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
    Michiels JJ, Gadisseur A, Budde U, Berneman Z, van der Planken M, Schroyens W, van de Velde A, van Vliet H.
    Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease.
    Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van de Velde A, van Vliet H.
    Clin Appl Thromb Hemost; 2006 Oct; 12(4):397-420. PubMed ID: 17000885
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prospective study of low-dose ristocetin-induced platelet aggregation to identify type 2B von Willebrand disease (VWD) and platelet-type VWD in children.
    Frontroth JP, Hepner M, Sciuccati G, Feliú Torres A, Pieroni G, Bonduel M.
    Thromb Haemost; 2010 Dec; 104(6):1158-65. PubMed ID: 20941465
    [Abstract] [Full Text] [Related]

  • 14. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin?
    Favaloro EJ.
    Semin Thromb Hemost; 2008 Feb; 34(1):113-27. PubMed ID: 18393148
    [Abstract] [Full Text] [Related]

  • 15. A first Taiwanese Chinese family of type 2B von Willebrand disease with R1306W mutation.
    Shen MC, Lin JS, Lin DS, Hsu SC, Lin B.
    Thromb Res; 2003 Feb; 112(5-6):291-5. PubMed ID: 15041272
    [Abstract] [Full Text] [Related]

  • 16. A Reliable von Willebrand factor: ristocetin cofactor enzyme-linked immunosorbent assay to differentiate between type 1 and type 2 von Willebrand disease.
    Vanhoorelbeke K, Cauwenberghs N, Vandecasteele G, Vauterin S, Deckmyn H.
    Semin Thromb Hemost; 2002 Apr; 28(2):161-6. PubMed ID: 11992239
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Clinical, laboratory and therapeutic aspects of platelet-type von Willebrand disease.
    Franchini M, Montagnana M, Lippi G.
    Int J Lab Hematol; 2008 Apr; 30(2):91-4. PubMed ID: 18333841
    [Abstract] [Full Text] [Related]

  • 19. Diagnosis of subtype 2B von Willebrand disease in a patient with 2A phenotype of plasma von Willebrand factor.
    Gaucher C, de Romeuf C, Rauïs-Morret M, Corazza F, Fondu P, Mazurier C.
    Thromb Haemost; 1995 Apr; 73(4):610-6. PubMed ID: 7495067
    [Abstract] [Full Text] [Related]

  • 20. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U.
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.